Previous studies show that overexpression of stathmin involved in the malignant biological behavior of lung cancer. This investigation is to disclose the expression status of stathmin in non-small cell lung cancer (NSCLC) and its clinical value for the diagnosis and prognosis to lung cancer.
METHODS:
The expression of stathmin in cells and tissues of NSCLC was examined using immunohistochemistry (IHC), in-situ hybridization (ISH), and Western blot. The correlation between stathmin expression and survival of lung cancer patients was evaluated by a Kaplan-Meier method and the multiple regression analysis.
RESULTS:
NSCLC tissues and cells showed an overexpression of stathmin compared with normal lung tissues and cells (p< 0.05). And the expression level of stathmin was significantly associated with lung adenocarcinoma (LAC) (p< 0.05), lymphatic invasion (p< 0.05) and advanced stages of NSCLC (p< 0.05). Moreover, overexpression of stathmin predicted a reduced survival (p<0.05).
CONCLUSION:
Increased stathmin correlated with pathologic grade, lymphatic invasion, advanced stage and poor survival of NSCLC, which indicated that stathmin could serve as a potential biomarker of NSCLC.
DurmG. and HannaN., Second-Line Chemotherapy and Beyond for Non-Small Cell Lung Cancer, Hematol Oncol Clin North Am31 (2017), 71-81.
2.
HeistR.S., First-Line Systemic Therapy for Non-Small Cell Lung Cancer, Hematol Oncol Clin North Am31 (2017), 59-70.
3.
ChenW., ZhengR., BaadeP.D., ZhangS., ZengH., BrayF., JemalA., YuX.Q. and HeJ., Cancer statistics in China, 2015, CA Cancer J Clin66 (2016), 115-132.
4.
BiaoxueR., XiguangC. and ShuanyingY., Annexin A1 in malignant tumors: current opinions and controversies, Int J Biol Markers29 (2014), e8-20.
5.
VillalobosP. and WistubaII., Lung Cancer Biomarkers, Hematol Oncol Clin North Am31 (2017), 13-29.
6.
YurongL., BiaoxueR., WeiL., ZongjuanM., HongyangS., PingF., WenlongG., ShuanyingY. and ZongfangL., Stathmin overexpression is associated with growth, invasion and metastasis of lung adenocarcinoma, Oncotarget DOI: 10.18632/oncotarget.11006 (2016).
7.
BellettiB. and BaldassarreG., Stathmin: A protein with many tasks. New biomarker and potential target in cancer, Expert Opin Ther Targets15 (2011), 1249-1266.
8.
KimJ.Y., HarvardC., YouL., XuZ., KuchenbeckerK., BaehnerR. and JablonsD., Stathmin is overexpressed in malignant mesothelioma, Anticancer Res27 (2007), 39-44.
9.
NakashimaD., UzawaK., KasamatsuA., KoikeH., EndoY., SaitoK., HashitaniS., NumataT., UradeM. and TanzawaH., Protein expression profiling identifies maspin and stathmin as potential biomarkers of adenoid cystic carcinoma of the salivary glands, Int J Cancer118 (2006), 704-713.
10.
NieW., XuM.D., GanL., HuangH., XiuQ. and LiB., Overexpression of stathmin 1 is a poor prognostic biomarker in non-small cell lung cancer, Lab Invest95 (2015), 56-64.
11.
BiaoxueR., XilingJ., ShuanyingY., WeiZ., XiguangC., JinsuiW. and MinZ., Upregulation of Hsp90-beta and annexin A1 correlates with poor survival and lymphatic metastasis in lung cancer patients, J Exp Clin Cancer Res31 (2012), 70.
12.
FioreE., CampaniD., MullerI., BelardiV., GiustariniE., RossiG., PincheraA. and GianiC., IGF-II mRNA expression in breast cancer: predictive value and relationship to other prognostic factors, Int J Biol Markers25 (2010), 150-156.
13.
KouzuY., UzawaK., KoikeH., SaitoK., NakashimaD., HigoM., EndoY., KasamatsuA., ShiibaM., BukawaH., YokoeH. and TanzawaH., Overexpression of stathmin in oral squamous-cell carcinoma: Correlation with tumour progression and poor prognosis, Br J Cancer94 (2006), 717-723.
14.
ReyesH., BosquetJ., StephanJ., McDonaldM. and LeslieK., Stathmin over-expression correlates with poor prognosis in patients with endometrial cancer, Gynecol Oncol137 (2015), 66.
15.
JeonT.Y., HanM.E., LeeY.W., LeeY.S., KimG.H., SongG.A., HurG.Y., KimJ.Y., KimH.J., YoonS., BaekS.Y., KimB.S., KimJ.B. and OhS.O., Overexpression of stathmin1 in the diffuse type of gastric cancer and its roles in proliferation and migration of gastric cancer cells, Br J Cancer102 (2010), 710-718.
16.
HsiehS.Y., HuangS.F., YuM.C., YehT.S., ChenT.C., LinY.J., ChangC.J., SungC.M., LeeY.L. and HsuC.Y., Stathmin1 overexpression associated with polyploidy, tumor-cell invasion, early recurrence, and poor prognosis in human hepatoma, Mol Carcinog49 (2010), 476-487.
17.
RongB., JiangX., YangS., ZhangW., CaiX., WangJ. and ZhangM., Upregulation of Hsp90-beta and annexin A1 correlates with poor survival and lymphatic metastasis in lung cancer patients, Journal of Experimental & Clinical Cancer Research31 (2012).
18.
YuanR.H., JengY.M., ChenH.L., LaiP.L., PanH.W., HsiehF.J., LinC.Y., LeeP.H. and HsuH.C., Stathmin overexpression cooperates with p53 mutation and osteopontin overexpression, and is associated with tumour progression, early recurrence, and poor prognosis in hepatocellular carcinoma, J Pathol209 (2006), 549-558.
19.
SonegoM., SchiappacassiM., LovisaS., Dall'AcquaA., BagnoliM., LovatF., LibraM., D'AndreaS., CanzonieriV. and MilitelloL., Stathmin regulates mutant p53 stability and transcriptional activity in ovarian cancer, EMBO Molecular Medicine5 (2013), 707-722.
20.
BiaoxueR., XiguangC., HuaL. and ShuanyingY., Stathmin-dependent molecular targeting therapy for malignant tumor: The latest 5 years' discoveries and developments, J Transl Med14 (2016), 279.
21.
WuY., TangM., WengX., YangL., XuW., YiW., GaoJ., BodeA.M., DongZ. and CaoY., A combination of paclitaxel and siRNA-mediated silencing of Stathmin inhibits growth and promotes apoptosis of nasopharyngeal carcinoma cells, Cell Oncol (Dordr)37 (2014), 53-67.
22.
YuanS.F., ChenW.J., ZhuL.J., ZhengW.E., ChenH. and XiongJ.P., Effects of monoclonal antibodies against human stathmin combined with paclitaxel on proliferation of the QG-56 human lung carcinoma cell line, Asian Pac J Cancer Prev13 (2012), 2967-2971.
23.
LongM., YinG., LiuL., LinF., WangX., RenJ., WeiJ., DongK. and ZhangH., Adenovirus-mediated Aurora A shRNA driven by stathmin promoter suppressed tumor growth and enhanced paclitaxel chemotherapy sensitivity in human breast carcinoma cells, Cancer Gene Ther19 (2012), 271-281.
24.
NieW., XuM.-D., GanL., HuangH., XiuQ. and LiB., Overexpression of stathmin 1 is a poor prognostic biomarker in non-small cell lung cancer, Laboratory Investigation95 (2015), 56-64.
